Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Jul 22 2010NewsGuard 100/100 Score

Tamir Biotechnology, Inc. (formerly Alfacell Corporation) (OTCBB:ACEL) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of two (2) of the company's compounds Onconase® (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.

In order to determine the effectiveness of a compound, NIAID uses a Selectivity Index (SI). The SI measures EC50 (50% virus-inhibitory (effective) concentration and EC90 (90%) cell inhibitory (cytotoxic) concentration determined in stationary cells.

"Many companies spend years in research and development and untold millions in the hope of developing a compound capable of demonstrating anti viral activity against a single virus. This week we've been able to report positive anti viral activity in Dengue  stated Charles Muniz, Chief Executive Officer of Tamir.

SOURCE Tamir Biotechnology, Inc.

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Scientists detect replication-competent Oropouche virus in semen of traveler, sparking transmission fears
AI-designed drug ISM5939 granted IND clearance for cancer clinical trials
CDC identifies new Oropouche virus cases in U.S. travelers, raising public health concerns
Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy
The World Vaccine Congress returns to Barcelona, Spain
Pasteurization effectively reduces H5N1 virus in milk but further testing is essential
Oropouche virus spreads in South America as scientists warn of potential outbreaks in the U.S.
Engineered virus-like particles evolve for superior gene delivery efficiency

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Elevated antibody responses to Epstein-Barr virus linked to increased risk of multiple sclerosis